Lexeo Therapeutics, Inc. Common Stock
LXEOAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jan 13, 2026 | H.C. Wainwright | Mitchell Kapoor | $10.00(+23%) | $8.12 | TheFly |
| Dec 17, 2025 | Raymond James | $25.00(+174%) | $9.11 | TheFly | |
| Dec 10, 2025 | Oppenheimer | Leland Gershell | $20.00(+110%) | $9.51 | StreetInsider |
| Nov 20, 2025 | Cantor Fitzgerald | $19.00(+109%) | $9.09 | TheFly | |
| Oct 21, 2025 | H.C. Wainwright | $13.00(+41%) | $9.22 | TheFly | |
| Oct 15, 2025 | Guggenheim | $30.00(+253%) | $8.50 | TheFly | |
| Oct 7, 2025 | Chardan Capital | $17.00(+106%) | $8.25 | TheFly | |
| Oct 7, 2025 | H.C. Wainwright | $15.00(+82%) | $8.25 | TheFly | |
| Oct 7, 2025 | Leerink Partners | Mani Foroohar | $20.00(+142%) | $8.25 | TheFly |
| Jun 12, 2024 | Robert W. Baird | Brian Skorney | $28.00(+54%) | $18.19 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Leerink Partners | maintain | Outperform | Sep 23, 2026 |
| JP Morgan | maintain | Overweight | Jun 25, 2026 |
| Chardan Capital | maintain | Buy | May 11, 2026 |
| Chardan Capital | maintain | Buy | Jan 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jan 13, 2026 |
| Chardan Capital | maintain | Buy | Dec 11, 2025 |
| Chardan Capital | maintain | Buy | Nov 5, 2025 |
| HC Wainwright & Co. | maintain | Buy | Oct 21, 2025 |
| Chardan Capital | maintain | Buy | Oct 7, 2025 |
| Leerink Partners | maintain | Outperform | Oct 7, 2025 |
| HC Wainwright & Co. | maintain | Buy | Oct 7, 2025 |
| Chardan Capital | maintain | Buy | Aug 15, 2025 |
| Leerink Partners | maintain | Outperform | Aug 15, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2025 |
| JP Morgan | maintain | Overweight | May 30, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 16, 2025 |
| Chardan Capital | maintain | Buy | May 13, 2025 |
| Leerink Partners | maintain | Outperform | May 12, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 8, 2025 |
| Chardan Capital | maintain | Buy | Apr 8, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 26, 2025 |
| RBC Capital | maintain | Outperform | Mar 25, 2025 |
| Chardan Capital | maintain | Buy | Mar 25, 2025 |
| Leerink Partners | maintain | Outperform | Mar 24, 2025 |
| RBC Capital | maintain | Outperform | Jan 21, 2025 |
Earnings History
Next report: Dec 14, 2026 · EPS est. $-0.32| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.30 | $-0.29 | — | — |
| May 11, 2026 | $-0.25 | $-0.29 | — | — |
| Mar 30, 2026 | $-0.27 | $-0.32 | — | — |
| Nov 5, 2025 | $-0.33 | $-0.48 | — | — |
| Aug 14, 2025 | $-0.60 | $-0.64 | — | — |
| May 12, 2025 | $-0.99 | $-0.80 | — | — |
| Mar 24, 2025 | $-0.78 | $-0.87 | — | — |
| Nov 13, 2024 | $-0.89 | $-0.65 | — | — |
News
Presentations at AHA to highlight Lexeo's cardiovascular gene therapy pipeline, including preclinical programs in desmoplakin and TNNI3 cardiomyopathies New LX2006 data to be presented at ICAR demonstrating cardiac and neurologic benefit up to 36 months, showing sustained or deepening improvement in mFARS outcomes over time NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unme…
Lexeo Therapeutics NASDAQ: LXEO outlined upcoming clinical and regulatory milestones for its gene therapy programs in Friedreich's ataxia cardiomyopathy and PKP2-associated arrhythmogenic cardiomyopathy during the Chardan Healthcare Conference.
Lexeo Therapeutics NASDAQ: LXEO outlined its approach to evaluating LX2020, an investigational AAVrh10-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy, or ACM, ahead of an expected clinical and regulatory update later this quarter.
Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy Transcript
NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that it will host an educational investor event, “Assessing clinically meaningful arrhythmias in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM)” on Wednesday, October 21, 2026 at 1:00 PM ET. The event will feature a discussion with Narinder Bhalla, M.D.
NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at Chardan's 10th Annual Healthcare Conference on October 20, 2026 at 9:30am ET. The event will be webcast live under the Events & Presentations tab in the Investors section of the Company's website.
Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control cohort from UNIFAI natural history study Presentation will include new mFARS subscore analyses providing additional insight into neurologic outcomes following LX2006 treatment NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on resha…
NEW YORK, Sept. 23, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, will provide Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, access to TfR1 CapX™ for a program designed to treat Friedreich ataxia.
NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00am ET.
Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript
Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace frataxin in the brain Collaborations launched to evaluate gene therapy sequential dosing following treatment with LX2006 and explore cerebellar targeting to optimize outcomes in FA associated neurological disease SUNRISE-FA 2 pivotal study continues enrollment and remains the company's top priority development program; topline data on track for 2H 2027 Disciplined capital allocation supports thes…
BlackRock Inc. acquired a new stake in Lexeo Therapeutics, Inc. (NASDAQ: LXEO) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 5,739,455 shares of the company's stock, valued at approximately $26,717,000. BlackRock Inc. owned about 7.31% of Lexeo Therapeutics at the end of
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in September: Cantor Global Healthcare Conference 2026.
Avoro Capital Advisors LLC purchased a new stake in Lexeo Therapeutics, Inc. (NASDAQ: LXEO) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 1,489,189 shares of the company's stock, valued at approximately $6,932,175,000. Lexeo Therapeutics makes up 0.1% of Avoro Capital Advisors LLC's
Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled into pivotal study in June; site activation efforts ongoing CLARITY-FA enrollment continues to advance, supporting identification of eligible participants for SUNRISE-FA 2 FDA granted RMAT designation for LX2020 based on recent interim clinical data in PKP2-ACM Cash, cash equivalent…